Sarilumab for treating Polyarticular-course Juvenile idiopathic arthritis in children and adolescents

Sarilumab is currently in clinical development for the treatment of children and adolescents aged 2-17 with polyarticular Juvenile Idiopathic Arthritis (JIA) or oligoarticular extended JIA subtype. Arthritis is inflammation of the joints, and juvenile idiopathic arthritis means the arthritis of unknown origin present in children and adolescents. Symptoms of polyarticular JIA include joint pain, swelling and stiffness, which can last from a few months to many years. There are currently limited treatment options for this patient group.